FDA gives tentative nod for Glenmark’s generic Qtern

The Food and Drug Administration has given Glenmark a tentative nod for dapagliflozin and saxagliptin tablets, a generic of AstraZeneca's Qtern. Glenmark's generic has been approved in a dosage strength of 10 mg/5 mg.

Qtern tablets, 10 mg/5 mg had a market value of approximately $10.4 million for the 12 months ended February 2020, according to IQVIA.